市场调查报告书
商品编码
1608880
乳癌近距离治疗市场:按技术、按应用、按最终用户、按地区Breast Cancer Brachytherapy Market, By Technology (High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy), By Application, By End User, By Geography |
预计2024年全球乳癌近距离治疗市场规模为8.981亿美元,预计2031年将达14.232亿美元,2024年至2031年复合年增长率为6.8%。
报告范围 | 报告详情 | ||
---|---|---|---|
基准年 | 2023年 | 2024年市场规模 | 8.981 亿美元 |
实际资料 | 2019-2023 | 预测期 | 2024年至2031年 |
预测 2024-2031 年复合年增长率: | 6.80% | 2031年价值预测 | 1,423.2 百万美元 |
乳癌近距离放射治疗是放射线治疗的一种形式,其中放射性粒子或导管直接放置到乳房组织。这允许将高剂量的辐射传递到相关区域,同时限制对周围健康组织的暴露。这种精准治疗在早期、低风险乳癌治疗中发挥重要作用,因为它可以实现高治癒率,同时避免通常丑陋的手术。乳房近距离放射治疗通常在肿瘤切除术后作为放射加强进行,或单独用于老年或无法手术的患者。由于人口老化和生活方式的改变,全球乳癌发生率持续上升,乳房近距离放射治疗市场预计在未来几年将稳定成长。
全球乳癌近距离放射治疗市场的成长是由全球乳癌发生率上升、人们对保乳治疗的偏好增加以及已开发国家对近距离放射治疗的有利报销政策所推动的。然而,向所有类型的患者提供近距离放射治疗的困难,加上人们认识到仅靠肿瘤切除术不足以治疗,正在阻碍市场潜力。关键的市场机会在于扩大乳房近距离放射治疗在开发中国家的使用,将其与高风险病例的化疗等其他治疗方法相结合,并确保放射肿瘤科医生得到充分的培训,特别是在资源匮乏的地区。
该报告对全球乳癌近距离放射治疗市场进行了详细分析,并提供了以2023年为基准年的预测期(2024-2031年)的市场规模和年复合成长率(CAGR%)。
它还揭示了各个细分市场的潜在商机,并说明了该市场有吸引力的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景、主要企业采取的竞争策略等的重要见解。
本研究涵盖的主要企业包括 Varian Medical Systems, Inc.、Elekta AB、Eckert &Ziegler BEBIG、iCAD, Inc.、Hologic, Inc.、Cianna Medical、IsoRay Medical, Inc.、Theragenics Corporation、CR Bard, Inc.、Boston Scientific Corporation、Merit Medical Systems、Cook Medical、SenoRx, Inc.、Nucletron BV 和Xoft, Inc.。
该报告的见解使负责人和公司经营团队能够就未来的产品发布、升级、市场扩张和行销策略做出明智的决策。
本研究报告针对该产业的各个相关人员,如投资者、供应商、产品製造商、经销商、新进业者和财务分析师。
透过用于分析全球乳癌近距离放射治疗市场的各种策略矩阵,将促进相关人员的决策。
The global breast cancer brachytherapy market is estimated to be valued at USD 898.1 Mn in 2024 and is expected to reach USD 1,423.2 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.8% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | 898.1 Mn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 6.80% | 2031 Value Projection: | 1,423.2 Mn |
Breast cancer brachytherapy is a form of radiation therapy that involves placing radioactive seeds or catheters directly inside breast tissue. It allows the delivery of higher doses of radiation to a contained area while lowering exposure to surrounding healthy tissues. This precision therapy plays an important role in early stage, low risk breast cancer treatment as it can often avoid disfiguring surgery while achieving high cure rates. Breast brachytherapy is typically delivered as radiation boost after lumpectomy, or used alone in elderly or medically inoperable patients. As breast cancer incidence continues rising globally due to aging populations and lifestyle changes, the breast brachytherapy market is positioned for steady growth over the coming years.
The global breast cancer brachytherapy market growth is driven by the rising breast cancer burden worldwide, growing preference for breast conserving therapies, and favorable reimbursement policies in developed countries for brachytherapy procedures. However, the market potential is hampered by difficulties in delivering brachytherapy to all patient types combined with the perception of lumpectomy alone being insufficient treatment. Key market opportunities lie in expanding the use of breast brachytherapy in developing nations, exploring combining it with other treatment modalities like chemotherapy to treat higher risk cases, and ensuring adequate training of radiation oncology specialists especially in low resource settings.
This report provides in-depth analysis of the global breast cancer brachytherapy market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
Key companies covered as a part of this study include Varian Medical Systems, Inc., Elekta AB, Eckert & Ziegler BEBIG, iCAD, Inc., Hologic, Inc., Cianna Medical, IsoRay Medical, Inc., Theragenics Corporation, C.R. Bard, Inc., Boston Scientific Corporation, Merit Medical Systems, Cook Medical, SenoRx, Inc., Nucletron B.V., and Xoft, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global breast cancer brachytherapy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global breast cancer brachytherapy market